Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04494724 · ClinicalTrials.gov registry record · Phase 2
Clazakizumab vs. Placebo - COVID-19 Infection
A Phase 2 study, sponsored by The Methodist Hospital Research Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT04494724 is a Phase 2 study that is actively recruiting participants, run by The Methodist Hospital Research Institute. The registered enrollment target is 60 participants.
The verdict
NCT04494724, a Phase 2 study, is actively recruiting participants, sponsored by The Methodist Hospital Research Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the effectiveness and safety of treatment with clazakizumab compared to a placebo (inactive substance). We are proposing to try this drug to treat coronavirus disease 2019 (COVID-19) infection. Patients with COVID-19 infection have been shown to have increases in certain inflammatory processes. Clazakizumab is an antibody (immune system protein) that blocks certain inflammatory processes. The treatment plan is to attempt to inhibit or block these inflammatory processes in order to try to limit the damage COVID-19 causes to the lungs.
Interventions
- DRUG Placebo
- DRUG Clazakizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2020-07-13 |
| Est. Completion | 2021-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04494724
The ClinicalTrials.gov registry entry for NCT04494724 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Methodist Hospital Research Institute, which has 126 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04494724 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04494724 about?
NCT04494724 is a clinical study titled "Clazakizumab vs. Placebo - COVID-19 Infection". The purpose of this study is to investigate the effectiveness and safety of treatment with clazakizumab compared to a placebo (inactive substance). We are proposing to try this drug to treat coronavirus disease 2019 (COVID-19) infection. Patients with COVID-19 infection have been shown to have incre...
What is the current status of trial NCT04494724?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2020-07-13. Estimated completion is 2021-07-31.
What interventions are being tested in trial NCT04494724?
The interventions under investigation include: Placebo (DRUG), Clazakizumab (DRUG).
Who is sponsoring clinical trial NCT04494724?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.